A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs INCB 54707 (Primary)
- Indications Hidradenitis suppurativa
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 24 Sep 2019 This trial has been completed in Denmark, according to European Clinical Trials registry record
- 02 Jan 2019 Status changed from not yet recruiting to recruiting.
- 12 Sep 2018 Planned primary completion date changed from 1 Oct 2019 to 1 Nov 2019.